The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A10 | Drugs used in diabetes | |
3
|
A10A | Insulins and analogues | |
4
|
A10AB | Insulins and analogues for injection, fast-acting |
| Code | Title | |
|---|---|---|
| A10AB01 | Insulin (human) | |
| A10AB02 | Insulin (beef) | |
| A10AB03 | Insulin (pork) | |
| A10AB04 | Insulin lispro | |
| A10AB05 | Insulin aspart | |
| A10AB06 | Insulin glulisine | |
| A10AB30 | Combinations |
| Active Ingredient |
|---|
|
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. |
|
|
|
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection. |
|
Insulin glulisine is a recombinant human insulin analogue that is equipotent to regular human insulin. Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin. |
|
The primary activity of insulin lispro is the regulation of glucose metabolism. |